

CLNE0022: Skeletal Muscle and Associated Diseases

View Online



1

Great Britain. Audit Commission for Local Authorities and the National Health Service in England and Wales. What Seems to Be the Matter Communication (National Health Service Report). Stationery Office
<https://webarchive.nationalarchives.gov.uk/20150410163038/http://archive.audit-commission.gov.uk/auditcommission/aboutus/publications/pages/national-reports-and-studies-archive.aspx.html>

2

An information leaflet for surgical patients. Annals of The Royal College of Surgeons of England 1983;**65**.<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2494353/>

3

Department of Health. Toolkit for Producing Patient Information, Version 2. 2003.<https://www.uea.ac.uk/documents/246046/0/Toolkit+for+producing+patient+information.pdf>

4

Garner M, Ning Z, Francis J. A framework for the evaluation of patient information leaflets. Health Expectations 2012;**15**:283–94. doi:10.1111/j.1369-7625.2011.00665.x

5

Prescription information leaflets: a pilot study in general practice. British Medical Journal (Clinical research ed) 1983;**287**.<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1549423/>

6

Berthelsen MP, Husu E, Christensen SB, et al. Anti-gravity training improves walking capacity and postural balance in patients with muscular dystrophy. *Neuromuscular Disorders* 2014;**24**:492–8. doi:10.1016/j.nmd.2014.03.001

7

Cup EH, Pieterse AJ, ten Broek-Pastoor JM, et al. Exercise Therapy and Other Types of Physical Therapy for Patients With Neuromuscular Diseases: A Systematic Review. *Archives of Physical Medicine and Rehabilitation* 2007;**88**:1452–64. doi:10.1016/j.apmr.2007.07.024

8

Voet NB, van der Kooi EL, Riphagen II, et al. Strength training and aerobic exercise training for muscle disease. *Cochrane Database of Systematic Reviews* Published Online First: 9 July 2013. doi:10.1002/14651858.CD003907.pub4

9

Sveen M-L, Andersen SP, Ingelsrud LH, et al. Resistance training in patients with limb-girdle and becker muscular dystrophies. *Muscle & Nerve* 2013;**47**:163–9. doi:10.1002/mus.23491

10

Jeppesen TD, Schwartz M, Olsen DB, et al. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. *Brain* 2006;**129**:3402–12. doi:10.1093/brain/awl149

11

Balance and walking involvement in facioscapulohumeral dystrophy: a pilot study on the effects of custom lower limb orthoses - *European Journal of Physical and Rehabilitation Medicine* 2013 April;49(2):169-78 - *Minerva Medica - Journals*.
<https://www.minervamedica.it/en/journals/europa-medicophysica/article.php?cod=R33Y2013N02A0169>

12

Institute of Neurology, Queen Square, National Hospital for Neurology and Neurosurgery (London, England). Neurology: a Queen Square textbook. Second edition. Chichester, West Sussex, UK: : John Wiley & Sons, Inc 2016.
<https://onlinelibrary.wiley.com/doi/book/10.1002/9781118486160>

13

Neuromuscular Disease Center. <https://neuromuscular.wustl.edu/>

14

Barohn RJ, Dimachkie MM, Jackson CE. A Pattern Recognition Approach to Patients with a Suspected Myopathy. Neurologic Clinics 2014;**32**:569–93. doi:10.1016/j.ncl.2014.04.008

15

Jones DA, Haan A de, Round JM. Skeletal muscle from molecules to movement: a textbook of muscle physiology for sport, exercise, physiotherapy and medicine. Edinburgh: : Churchill Livingstone 2004.

16

By:Gordon, AM (Gordon, AM); Homsher, E (Homsher, E); Regnier, M (Regnier, M). Regulation of contraction in striated muscle. PHYSIOLOGICAL REVIEWS PHYSIOLOGICAL REVIEWS 2000;**80**:853–924.http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=13&SID=C49BOGnSGP9s3PqA3ow&page=1&doc=1

17

Force-velocity properties of human skeletal muscle fibres: myosin heavy chain isoform and temperature dependence. The Journal of Physiology 1996;**495**.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1160815/>

18

Harridge SDR, Bottinelli R, Canepari M, et al. Whole-muscle and single-fibre contractile properties and myosin heavy chain isoforms in humans. *Pflügers Archiv - European Journal of Physiology* 1996;**432**:913–20. doi:10.1007/s004240050215

19

Hunter S, White M, Thompson M. Techniques to Evaluate Elderly Human Muscle Function: A Physiological Basis. *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences* 1998;**53A**:B204–16. doi:10.1093/gerona/53A.3.B204

20

O'Brien TD, Reeves ND, Baltzopoulos V, et al. In vivo measurements of muscle specific tension in adults and children. *Experimental Physiology* 2010;**95**:202–10. doi:10.1113/expphysiol.2009.048967

21

Atherton PJ, Smith K. Muscle protein synthesis in response to nutrition and exercise. *The Journal of Physiology* 2012;**590**:1049–57. doi:10.1113/jphysiol.2011.225003

22

Baar K. Using Molecular Biology to Maximize Concurrent Training. *Sports Medicine* 2014;**44**:117–25. doi:10.1007/s40279-014-0252-0

23

Rennie MJ, Wackerhage H, Spangenburg EE, et al. Control of the Size of the Human Muscle Mass. *Annual Review of Physiology* 2004;**66**:799–828. doi:10.1146/annurev.physiol.66.052102.134444

24

Kadi F. Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. *British Journal of Pharmacology* 2008;**154**:522–8. doi:10.1038/bjp.2008.118

25

Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. *British Journal of Pharmacology* 2008;**154**:557–68. doi:10.1038/bjp.2008.153

26

Marcotte GR, West DWD, Baar K. The Molecular Basis for Load-Induced Skeletal Muscle Hypertrophy. *Calcified Tissue International* 2015;**96**:196–210. doi:10.1007/s00223-014-9925-9

27

Egner IM, Bruusgaard JC, Eftestøl E, et al. A cellular memory mechanism aids overload hypertrophy in muscle long after an episodic exposure to anabolic steroids. *The Journal of Physiology* 2013;**591**:6221–30. doi:10.1113/jphysiol.2013.264457

28

Atherton PJ, Smith K. Muscle protein synthesis in response to nutrition and exercise. *The Journal of Physiology* 2012;**590**:1049–57. doi:10.1113/jphysiol.2011.225003

29

Fitts RH, Trappe SW, Costill DL, et al. Prolonged space flight-induced alterations in the structure and function of human skeletal muscle fibres. *The Journal of Physiology* 2010;**588**:3567–92. doi:10.1113/jphysiol.2010.188508

30

By: Jones, SW (Jones, SW); Hill, RJ (Hill, RJ); Krasney, PA (Krasney, PA); O'Conner, B (O'Conner, B); Peirce, N (Peirce, N); Greenhaff, PL (Greenhaff, PL). Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle mass. *FASEB JOURNAL* FASEB JOURNAL 2004;**18**. doi:10.1096/fj.03-1228fje

31

Rennie MJ, Wackerhage H, Spangenburg EE, et al. Control of the Size of the Human Muscle Mass. *Annual Review of Physiology* 2004;**66**:799–828.
doi:10.1146/annurev.physiol.66.052102.134444

32

Shavlakadze T, Grounds M. Of bears, frogs, meat, mice and men: complexity of factors affecting skeletal muscle mass and fat. *BioEssays* 2006;**28**:994–1009.
doi:10.1002/bies.20479

33

Puthuchery ZA, Rawal J, McPhail M, et al. Acute Skeletal Muscle Wasting in Critical Illness. *JAMA* 2013;**310**. doi:10.1001/jama.2013.278481

34

Wiggs MP. Can endurance exercise preconditioning prevention disuse muscle atrophy? *Frontiers in Physiology* 2015;**6**. doi:10.3389/fphys.2015.00063

35

Baar K. Using Molecular Biology to Maximize Concurrent Training. *Sports Medicine* 2014;**44**:117–25. doi:10.1007/s40279-014-0252-0

36

Craig DM, Ashcroft SP, Belew MY, et al. Utilizing small nutrient compounds as enhancers of exercise-induced mitochondrial biogenesis. *Frontiers in Physiology* 2015;**6**.
doi:10.3389/fphys.2015.00296

37

Hoier B, Hellsten Y. Exercise-Induced Capillary Growth in Human Skeletal Muscle and the Dynamics of VEGF. *Microcirculation* 2014;**21**:301–14. doi:10.1111/micc.12117

38

Hardie DG, Sakamoto K. AMPK: A Key Sensor of Fuel and Energy Status in Skeletal Muscle. *Physiology* 2006;**21**:48–60. doi:10.1152/physiol.00044.2005

39

Hawley JA, Hargreaves M, Joyner MJ, et al. Integrative Biology of Exercise. *Cell* 2014;**159**:738–49. doi:10.1016/j.cell.2014.10.029

40

Briggs D, Morgan JE. Recent progress in satellite cell/myoblast engraftment - relevance for therapy. *FEBS Journal* 2013;**280**:4281–93. doi:10.1111/febs.12273

41

Zammit PS, Golding JP, Nagata Y, et al. Muscle satellite cells adopt divergent fates. *The Journal of Cell Biology* 2004;**166**:347–57. doi:10.1083/jcb.200312007

42

Boldrin L, Morgan JE. Activating muscle stem cells: therapeutic potential in muscle diseases. *Current Opinion in Neurology* 2007;**20**:577–82. doi:10.1097/WCO.0b013e3282ef5919

43

Boldrin L, Zammit PS, Morgan JE. Satellite cells from dystrophic muscle retain regenerative capacity. *Stem Cell Research* 2015;**14**:20–9. doi:10.1016/j.scr.2014.10.007

44

Ross J, Benn A, Jonuschies J, et al. Defects in Glycosylation Impair Satellite Stem Cell Function and Niche Composition in the Muscles of the Dystrophic Large Mouse. *STEM CELLS* 2012;**30**:2330–41. doi:10.1002/stem.1197

45

Neuropathology and Applied Neurobiology. ; **Volume 43, Issue 1**
. <https://onlinelibrary.wiley.com/toc/13652990/2017/43/1>

46

Dubowitz V, Sewry CA, Oldfors A. Muscle biopsy: a practical approach. Fourth edition. [Philadelphia, Pa.]: : Saunders Elsevier 2013.

47

Hollingsworth KG, de Sousa PL, Straub V, et al. Towards harmonization of protocols for MRI outcome measures in skeletal muscle studies: Consensus recommendations from two TREAT-NMD NMR workshops, 2 May 2010, Stockholm, Sweden, 1–2 October 2009, Paris, France. *Neuromuscular Disorders* 2012; **22**:S54–67. doi:10.1016/j.nmd.2012.06.005

48

Wattjes MP, Fischer D. Neuromuscular imaging. New York: : Springer 2013.
http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3320980190004761&institutionId=4761&customerId=4760

49

Forbes SC, Willcocks RJ, Triplett WT, et al. Magnetic Resonance Imaging and Spectroscopy Assessment of Lower Extremity Skeletal Muscles in Boys with Duchenne Muscular Dystrophy: A Multicenter Cross Sectional Study. *PLoS ONE* 2014; **9**. doi:10.1371/journal.pone.0106435

50

Glover GH, Schneider E. Three-point dixon technique for true water/fat decomposition with B₀ inhomogeneity correction. *Magnetic Resonance in Medicine* 1991; **18**:371–83. doi:10.1002/mrm.1910180211

51

Willcocks RJ, Rooney WD, Triplett WT, et al. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort. *Annals of*

Neurology 2016;**79**:535–47. doi:10.1002/ana.24599

52

Hogrel J-Y, Wary C, Moraux A, et al. Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy. *Neurology* 2016;**86**:1022–30. doi:10.1212/WNL.0000000000002464

53

Kim HK, Serai S, Lindquist D, et al. Quantitative Skeletal Muscle MRI: Part 2, MR Spectroscopy and T2 Relaxation Time Mapping—Comparison Between Boys With Duchenne Muscular Dystrophy and Healthy Boys. *American Journal of Roentgenology* 2015;**205**:W216–23. doi:10.2214/AJR.14.13755

54

Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. *The Lancet Neurology* 2003;**2**:731–40. doi:10.1016/S1474-4422(03)00585-4

55

Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. *The Lancet Neurology* 2010;**9**:77–93. doi:10.1016/S1474-4422(09)70271-6

56

Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. *The Lancet Neurology* 2010;**9**:177–89. doi:10.1016/S1474-4422(09)70272-8

57

Ricotti V, Ridout DA, Scott E, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. *Journal of Neurology, Neurosurgery & Psychiatry* 2013;**84**:698–705. doi:10.1136/jnnp-2012-303902

58

Goemans NM, Tulinius M, van den Akker JT, et al. Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy. *New England Journal of Medicine* 2011;**364**:1513-22. doi:10.1056/NEJMoa1011367

59

Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. *Annals of Neurology* 2013;**74**:637-47. doi:10.1002/ana.23982

60

Mendell JR, Goemans N, Lowes LP, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. *Annals of Neurology* 2016;**79**:257-71. doi:10.1002/ana.24555

61

Kinali M, Arechavala-Gomez V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. *The Lancet Neurology* 2009;**8**:918-28. doi:10.1016/S1474-4422(09)70211-X

62

Cirak S, Arechavala-Gomez V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. *The Lancet* 2011;**378**:595-605. doi:10.1016/S0140-6736(11)60756-3

63

Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. *Muscle & Nerve* 2014;**50**:477-87. doi:10.1002/mus.24332

64

Paganoni S, Amato A. Electrodiagnostic Evaluation of Myopathies. *Physical Medicine and Rehabilitation Clinics of North America* 2013;**24**:193–207. doi:10.1016/j.pmr.2012.08.017

65

Fuglsang-Frederiksen A. The role of different EMG methods in evaluating myopathy. *Clinical Neurophysiology* 2006;**117**:1173–89. doi:10.1016/j.clinph.2005.12.018

66

Machado P, Brady S, Hanna MG. Update in inclusion body myositis. *Current Opinion in Rheumatology* 2013;**25**:763–71. doi:10.1097/01.bor.0000434671.77891.9a

67

Machado PM, Dimachkie MM, Barohn RJ. Sporadic inclusion body myositis. *Current Opinion in Neurology* 2014;**27**:591–8. doi:10.1097/WCO.0000000000000129

68

Machado PM, Ahmed M, Brady S, et al. Ongoing Developments in Sporadic Inclusion Body Myositis. *Current Rheumatology Reports* 2014;**16**. doi:10.1007/s11926-014-0477-9

69

Ahmed M, Machado PM, Miller A, et al. Targeting protein homeostasis in sporadic inclusion body myositis. *Science Translational Medicine* 2016;**8**:331ra41–331ra41. doi:10.1126/scitranslmed.aad4583

70

Needham M, Mastaglia FL. Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment. *Clinical Neurophysiology* 2016;**127**:1764–73. doi:10.1016/j.clinph.2015.12.011

71

Schröder R, Schoser B. Myofibrillar Myopathies: A Clinical and Myopathological Guide. *Brain Pathology* 2009;**19**:483–92. doi:10.1111/j.1750-3639.2009.00289.x

72

Amato AA, Greenberg SA. Inflammatory Myopathies. *CONTINUUM: Lifelong Learning in Neurology* 2013;**19**:1615–33. doi:10.1212/01.CON.0000440662.26427.bd

73

Olivé M, Kley RA, Goldfarb LG. Myofibrillar myopathies. *Current Opinion in Neurology* 2013;**26**:527–35. doi:10.1097/WCO.0b013e328364d6b1

74

Carstens P-O, Schmidt J. Diagnosis, pathogenesis and treatment of myositis: recent advances. *Clinical & Experimental Immunology* 2014;**175**:349–58. doi:10.1111/cei.12194

75

Dalakas MC. Inflammatory Muscle Diseases. *New England Journal of Medicine* 2015;**372**:1734–47. doi:10.1056/NEJMra1402225

76

Darras BT, De Vivo DC, Jones HR. *Neuromuscular disorders of infancy, childhood, and adolescence: a clinician's approach*. Philadelphia, Penn. ; London: : Butterworth-Heinemann 2003.

77

Baioni MTC, Ambiel CR. Spinal muscular atrophy: diagnosis, treatment and future prospects. *Jornal de Pediatria* 2010;**86**:261–70. doi:10.2223/JPED.1988

78

Rudnik-Schöneborn S, Hausmanowa-Petrusewicz I, Borkowska J, et al. The Predictive Value of Achieved Motor Milestones Assessed in 441 Patients with Infantile Spinal Muscular Atrophy Types II and III. *European Neurology* 2001;**45**:174–81. doi:10.1159/000052118

79

Russman BS, Buncher CR, White M, et al. Function changes in spinal muscular atrophy II and III. *Neurology* 1996;**47**:973–6. doi:10.1212/WNL.47.4.973

80

Wang CH, Finkel RS, Bertini ES, et al. Consensus Statement for Standard of Care in Spinal Muscular Atrophy. *Journal of Child Neurology* 2007;**22**:1027–49. doi:10.1177/0883073807305788

81

Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. *The Lancet Neurology* 2012;**11**:443–52. doi:10.1016/S1474-4422(12)70061-3

82

Hollak CEM, Lachmann R, editors. *Inherited Metabolic Disease in Adults*. Oxford University Press 2016. doi:10.1093/med/9780199972135.001.0001

83

Nancy D Leslie. Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency. *Gene Reviews* Published Online First: 2018. <https://www.ncbi.nlm.nih.gov/books/NBK6816/>

84

Thomas Wieser. Carnitine Palmitoyltransferase II Deficiency. *Gene Reviews* Published Online First: 2017. <https://www.ncbi.nlm.nih.gov/books/NBK1253/>

85

Miguel A Martín. Glycogen Storage Disease Type V. Gene Reviews Published Online First: 2014. <https://www.ncbi.nlm.nih.gov/books/NBK1344/>

86

Nancy Leslie. Pompe Disease. Gene Reviews Published Online First: 2017. <https://www.ncbi.nlm.nih.gov/books/NBK1261/>

87

Ørngreen MC, Vissing J. Treatment Opportunities in Patients With Metabolic Myopathies. *Current Treatment Options in Neurology* 2017;**19**. doi:10.1007/s11940-017-0473-2

88

Olpin SE, Murphy E, Kirk RJ, et al. The investigation and management of metabolic myopathies. *Journal of Clinical Pathology* 2015;**68**:410–7. doi:10.1136/jclinpath-2014-202808

89

Feingold B, Mahle WT, Auerbach S, et al. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. *Circulation* 2017;**136**. doi:10.1161/CIR.0000000000000526

90

Matthews E, Hanna MG. Skeletal muscle channelopathies. In: Hilton-Jones D, Turner MR, eds. *Oxford Textbook of Neuromuscular Disorders*. Oxford University Press 2014. 316–25. doi:10.1093/med/9780199698073.003.0031

91

Hollak CEM, Lachmann R, editors. *Inherited Metabolic Disease in Adults*. Oxford University Press 2016. doi:10.1093/med/9780199972135.001.0001

92

Saudubray JM, Baumgartner MR, Walter J, editors. Inborn metabolic diseases: diagnosis and treatment. 6th edition. Berlin: : Springer 2016.

93

Hoffmann GF, Zschocke J, Nyhan WL, editors. Inherited metabolic diseases: a clinical approach. Second edition. Berlin: : Springer 2017.